CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions

At the time of writing, five anti-CD19 CAR T-cell products are approved by U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric acute lymphoblastic leukemia, multiple myeloma. T cells chronic lymphocytic myeloid less common malignancies such as lymphomas Hodgkin lymphoma being tested early-phase clinical trials worldwide. The purpose this overview is to describe current landscape hematologic outline their outcomes toxicities, explain outstanding questions that remain be addressed.